Insmed Incorporated

DB:IM8N Stock Report

Market Cap: €11.8b

Insmed Management

Management criteria checks 2/4

Insmed's CEO is Will Lewis, appointed in Sep 2012, has a tenure of 12.25 years. total yearly compensation is $10.41M, comprised of 7.5% salary and 92.5% bonuses, including company stock and options. directly owns 0.37% of the company’s shares, worth €44.31M. The average tenure of the management team and the board of directors is 5.1 years and 10.6 years respectively.

Key information

Will Lewis

Chief executive officer

US$10.4m

Total compensation

CEO salary percentage7.5%
CEO tenure12.3yrs
CEO ownership0.4%
Management average tenure5.1yrs
Board average tenure10.6yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Will Lewis's remuneration changed compared to Insmed's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$864m

Jun 30 2024n/an/a

-US$803m

Mar 31 2024n/an/a

-US$747m

Dec 31 2023US$10mUS$780k

-US$750m

Sep 30 2023n/an/a

-US$724m

Jun 30 2023n/an/a

-US$696m

Mar 31 2023n/an/a

-US$547m

Dec 31 2022US$8mUS$735k

-US$482m

Sep 30 2022n/an/a

-US$434m

Jun 30 2022n/an/a

-US$416m

Mar 31 2022n/an/a

-US$438m

Dec 31 2021US$7mUS$710k

-US$435m

Sep 30 2021n/an/a

-US$424m

Jun 30 2021n/an/a

-US$375m

Mar 31 2021n/an/a

-US$319m

Dec 31 2020US$6mUS$660k

-US$294m

Sep 30 2020n/an/a

-US$245m

Jun 30 2020n/an/a

-US$242m

Mar 31 2020n/an/a

-US$247m

Dec 31 2019US$7mUS$641k

-US$254m

Sep 30 2019n/an/a

-US$293m

Jun 30 2019n/an/a

-US$320m

Mar 31 2019n/an/a

-US$330m

Dec 31 2018US$6mUS$610k

-US$324m

Compensation vs Market: Will's total compensation ($USD10.41M) is above average for companies of similar size in the German market ($USD4.80M).

Compensation vs Earnings: Will's compensation has increased whilst the company is unprofitable.

CEO

Will Lewis (55 yo)

12.3yrs

Tenure

US$10,411,260

Compensation

Mr. William H. Lewis, also known as Will, J.D. M.B.A. serves as an Independent Chairman of Board of Directors of NewAmsterdam Pharma Company N.V. from January 2024. He has been Chief Executive Officer and...

Leadership Team

NamePositionTenureCompensationOwnership
William Lewis
President12.3yrsUS$10.41m0.37%
€ 44.3m
Sara Bonstein
Chief Financial Officer4.9yrsUS$4.56m0.010%
€ 1.2m
Roger Adsett
Chief Operating Officer5.1yrsUS$4.01m0.036%
€ 4.2m
John Wise
Chief Commercial Officer5.1yrsUS$3.89m0.029%
€ 3.4m
Martina Flammer
Chief Medical Officer5yrsUS$4.22m0.0071%
€ 840.8k
Brian Kaspar
Chief Scientific Officerno datano datano data
Eleanor Barisser
Associate Director of Investor Relationsno datano datano data
Michael Smith
Chief Legal Officer & Corporate Secretary3.4yrsno data0.038%
€ 4.5m
Mandy Fahey
Executive Director of Corporate Communicationsno datano datano data
S. Schaeffer
Chief People Strategy Officer11.9yrsUS$2.66m0.019%
€ 2.3m
Eugene Sullivan
Chief Product Strategy Officer7.6yrsUS$1.69mno data
Neil Hughes
GM & Head of Europe5.5yrsno datano data

5.1yrs

Average Tenure

55yo

Average Age

Experienced Management: IM8N's management team is seasoned and experienced (5.1 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
William Lewis
President12.3yrsUS$10.41m0.37%
€ 44.3m
David W. McGirr
Independent Director11.2yrsUS$320.00k0.048%
€ 5.7m
Melvin Sharoky
Independent Director23.6yrsUS$312.50k0.18%
€ 21.5m
Alfred Altomari
Independent Director12.3yrsUS$320.00k0.031%
€ 3.7m
David Brennan
Lead Independent Director10.6yrsUS$345.00k0.061%
€ 7.2m
Clarissa Desjardins
Independent Director5.1yrsUS$315.00k0.027%
€ 3.2m
Elizabeth Anderson
Independent Director6.1yrsUS$310.00k0.031%
€ 3.7m
Leo Lee
Independent Director6.6yrsUS$317.50k0.062%
€ 7.4m
Carol Schafer
Independent Director4.7yrsUS$315.00k0.025%
€ 3.0m

10.6yrs

Average Tenure

65yo

Average Age

Experienced Board: IM8N's board of directors are seasoned and experienced ( 10.6 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/31 19:56
End of Day Share Price 2024/12/02 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Insmed Incorporated is covered by 33 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Neena Bitritto-GargBaird
Leon WangBarclays
Anita DushyanthBerenberg